Moteur de recherche d’entreprises européennes
Financement de l’UE (4 260 221 €) : Perturber le continuum de soins de la migraine dans les milieux aux ressources limitées Hor01/09/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Perturber le continuum de soins de la migraine dans les milieux aux ressources limitées
Chronic migraine is defined as a headache persistent for more than 3 months or a severe headache persistent for more than 15 days within a month. It affects approximately 2% of the world population. The World Health Organization classifies severe migraine attacks as among the most disabling illnesses, comparable to dementia and quadriplegia. Treatments start with pharmaceutical drugs, which have contra-indications and severe side effects and often remain ineffective in chronic migraine patients. Injectable treatments like Botox and nerve blocks can be effective but require multiple sessions per year and also have undesirable effects. Treatments using neurostimulation products that deliver electrical pulses to the occipital nerve have been up to 80% effective but they are designed for the back not the neck which results in high rates of surgical revisions. This leaves the chronic migraine population severely underserved and in need of an innovative solution. Our vision is fundamentally based on disrupting the continuum of care and referral pathway by creating a more effective non-surgical solution that reduces cost and risk and therefore increases accessibility to more physicians and patients. The consortium will develop a novel platform for the treatment of chronic migraine that will be particularly applicable to resource restricted environments and targeting underserved patients. We are working on 4 elements working together seamlessly. 1) LUNA-AIR: An implantable electronics device with neural write stimulation 2) LUNA-CONTROL: A wearable device that will communicate with and power the implantable device. 3) LUNA-APP; a mobile app to control the implant. 4) LUNA-INJECT; an ergonomic, minimally invasive, injection device that minimises tissue trauma and training required for physicians.
| Centre for Process Innovation Ltd. LBG | ? |
| Brai3N | 323 196 € |
| Capri Medical Ltd. | 1 755 260 € |
| Crowdhelix Ltd. | 371 620 € |
| Sensichips Srl | 481 250 € |
| Skein-Ukraine | 530 833 € |
| Universita Di Pisa | 358 334 € |
| Univerzitetni klinicni center Maribor | 439 729 € |
https://cordis.europa.eu/project/id/101057524
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Centre for Process Innovation Ltd. LBG, Redcar Cleveland, Royaume Uni.
